Cargando…

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer

Our aim was to systematically evaluate the benefits of degarelix as antagonist versus agonists of gonadotropin-releasing hormones (GnRH) for the treatment of advanced prostate cancer (PC). This comparison was performed either in terms of biochemical or oncological or safety profiles. To this end we,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sciarra, Alessandro, Fasulo, Andrea, Ciardi, Antonio, Petrangeli, Elisa, Gentilucci, Alessandro, Maggi, Martina, Innocenzi, Michele, Pierella, Federico, Gentile, Vincenzo, Salciccia, Stefano, Cattarino, Susanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	7300
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058791/ https://www.ncbi.nlm.nih.gov/pubmed/27399062 http://dx.doi.org/10.1097/MD.0000000000003845

Ejemplares similares

Laparoscopic versus open radical prostatectomy in high prostate volume cases: impact on oncological and functional results
por: Alessandro, Sciarra, et al.
Publicado: (2016)

Cribriform pattern does not have a significant impact in Gleason Score ≥7/ISUP Grade ≥2 prostate cancers submitted to radical prostatectomy
por: Flammia, Simone, et al.
Publicado: (2020)

Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review
por: Sciarra, Alessandro, et al.
Publicado: (2016)

Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies
por: Sciarra, Alessandro, et al.
Publicado: (2021)

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer: Erratum
Publicado: (2016)

Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study
por: Porreca, Angelo, et al.
Publicado: (2020)

Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review
por: Sciarra, Alessandro, et al.
Publicado: (2019)

Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma
por: Silvestri, Ida, et al.
Publicado: (2013)

Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?
por: Sciarra, Alessandro, et al.
Publicado: (2023)

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

Exosome Analysis in Prostate Cancer: How They Can Improve Biomarkers’ Performance
por: Salciccia, Stefano, et al.
Publicado: (2023)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

Preoperative Serum Sex Hormone-Binding Globulin Level Is an Independent Predictor of Biochemical Outcome After Radical Prostatectomy
por: Lee, Jung Keun, et al.
Publicado: (2015)

Hyperhomocysteinemia as an Early Predictor of Erectile Dysfunction: International Index of Erectile Function (IIEF) and Penile Doppler Ultrasound Correlation With Plasma Levels of Homocysteine
por: Giovannone, Riccardo, et al.
Publicado: (2015)

How to Predict Outcomes from a Biofeedback and Pelvic Floor Muscle Electric Stimulation Program in Patients with Urinary Incontinence after Radical Prostatectomy
por: Salciccia, Stefano, et al.
Publicado: (2021)

Effect of Hypertension on Outcomes of High-Risk Patients After BCG-Treated Bladder Cancer: A Single-Institution Long Follow-Up Cohort Study
por: Dal Moro, Fabrizio, et al.
Publicado: (2015)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021)

Acupuncture combined with tamsulosin hydrochloride sustained-release capsule in the treatment of chronic prostatitis/chronic pelvic pain syndrome: A study protocol for a randomized controlled trial
por: Wang, Ji-Sheng, et al.
Publicado: (2020)

Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy
por: Bianchi, Roberto, et al.
Publicado: (2016)

Variation of DNA Fragmentation Levels During Density Gradient Sperm Selection for Assisted Reproduction Techniques: A Possible New Male Predictive Parameter of Pregnancy?
por: Muratori, Monica, et al.
Publicado: (2016)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
por: Zhou, Feng, et al.
Publicado: (2016)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
por: Yilmaz, Nafiye, et al.
Publicado: (2019)

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer
por: Mastandrea, Katherine, et al.
Publicado: (2023)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

Outcomes of robot-assisted simple enucleation of renal masses: A single European center experience
por: Matei, Deliu Victor, et al.
Publicado: (2017)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience
por: Ferro, Matteo, et al.
Publicado: (2015)

How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients
por: Sciarra, Alessandro, et al.
Publicado: (2022)

Prognostic Value of Albumin to Globulin Ratio in Non-Metastatic and Metastatic Prostate Cancer Patients: A Meta-Analysis and Systematic Review
por: Salciccia, Stefano, et al.
Publicado: (2022)

A 7-Year Retrospective Multisource Analysis on the Incidence of Anesthesia Awareness With Recall in Cancer Patients: A Chance of Collaboration Between Anesthesiologists and Psycho-Oncologists for Awareness Detection
por: Cascella, Marco, et al.
Publicado: (2016)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Which factors can influence post-operative renal function preservation after nephron-sparing surgery for kidney cancer: a critical review
por: Di Lascio, Giovanni, et al.
Publicado: (2022)

Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger)
por: de Oliveira, Sofia Andrade, et al.
Publicado: (2016)

Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats
por: TUNGMAHASUK, Doungrut, et al.
Publicado: (2017)

Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination
por: Halim, Binarwan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_86ov8cfkmi056da33gipvgpug2